retatrutide type 2 diabetes phase 2 trial 2024 Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, 3 Clinical trials of subcutaneous tirzepatide,

Modulatory Effects of BPC 157 on Vasomotor Tone and the Activation of Src-Caveolin-1-Endothelial Nitric Oxide Synthase Pathway

Abnormal locomotor behavior is one of the key symptoms or comorbidities observed in individuals with several neurological diseases and mental disorders, such as Parkinsons disease, Huntingtons disease, depression, anxiety, and psychosis 4,5,6,7

Conquering the Queasiness: How to Handle Nausea on Your GLP-1 Journey If you are taking a GLP-1 (like semaglutide) or a GLP-1/GIP (like tirzepatide) medication, you might be experiencing a "love-hate" relationship: you love the weight loss results, but you hate the occasional wave of nausea

it's working well for my goals

As demand for weight-loss drugs rises, states grapple with Medicaid coverage Some researchers question long-term cost savings for state programs Boxes of the diabetes drug Ozempic rest on a pharmacy counter